Contact information
Type
Scientific
Primary contact
Prof Juergen Schrezenmeir
ORCID ID
Contact details
Bundesforschungsanstalt für Ernährung und Lebensmittel
Standort Kiel
Institut für Physiologie und Biochemie der Ernährung
Hermann-Weigmann-Str. 1
Kiel
24103
Germany
+49 (0)431 609 2220
juergen.schrezenmeir@bfel.de
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
Acronym
CLA2 (Conjugated linoleic acid 2)
Study hypothesis
Conjugated Linoleic Acid (CLA) may beneficially affect lipid and glucose metabolism, inflammatory responses and body weight. These aspects are of relevance for subjects afflicted with or prone to develop so called metabolic syndrome, which is characterized by an insulin resistance, dyslipidaemia, essential hypertension and adiposity of the central type and frequently leads to early manifestation of type 2 diabetes mellitus, increased vascular risk and risk of atherosclerosis.
Studies of the influence of dietary CLA, namely the individual isomers cis9,trans11-CLA and trans10,cis12-CLA as well as the commercially available 50:50 mixture of these isomers, as compared to linoleic acid as control, on fasting and postprandial metabolism. The study will test if there are genotype-dependent specific effects of the PPARγ2 P12A polymorphism (P12P versus A12A homozygosity). Expression of genes relevant for inflammation and metabolic regulation will be examined in monocytes independent of a PPARγ2 polymorphism. Further parameters to assess atherogenic processes are the expression of adhesion molecules (ICAM, VCAM, E-Selectin). Low Density Lipoprotein (LDL) will be isolated and tested for adhesion molecules expression on endothelial cells. As another study reported that a mixture of CLA isomers impairs endothelial function, this parameter will be determined in our study, with particular attention for the effect of individual isomers. As dietary fats may acutely change endothelial function, this parameter is tested both in the fasting state and following a fat-rich meal. Genotype-dependent specific effects on fat tissue are to be examined by determining the gene expression profile of the subcutaneous fat tissue. Furthermore the effect of CLA on fecal flora will be assessed.
Ethics approval
Ethic Committee of the Medical Faculty of the Christian-Albrechts-University of Kiel, (Germany), approved on 13.09.2006 (ref: A151/06)
Study design
Randomised, double-blind, placebo-controlled, interventional, crossover study.
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Not specified
Trial type
Not Specified
Patient information sheet
Condition
Not applicable
Intervention
All participants will consume, in random order, capsules with either the individual isomers cis9,trans11-CLA and trans10,cis12-CLA as well as the commercially available 50:50 mixture of these isomers, and linoleic acid as control. The material is provided as free fatty acids in capsules. Tocopherol content of the preparations is standardized.
Each intervention will last for 4 weeks, interrupted by wash-out periods of 6-9 weeks between the interventions.
Intervention type
Drug
Phase
Not Specified
Drug names
Conjugated Linoleic Acid
Primary outcome measures
Change of postprandial triglyceride levels (Area Under the Curve [AUC]) after 28 (±2) days supplementation. Postprandial triglyceride levels will be measured at the start of the study and after each intervention period.
Secondary outcome measures
Measurements for the following will be made at the start of the study and after each intervention period.
Changes in:
1. Fasting and postprandial insulin (AUC)
2. Fasting and postprandial glucose (AUC)
3. Endothelial function (PAT-Index)
4. Body Mass Index (BMI)
5. Waist circumference (WC)
6. Waist to hip ratio (WHR)
7. Blood pressure, pulse
8. HOMA (Insulin-glucose-product)
9. Metabolic regulatory parameters, namely:
9.1. Glucose dependent insulinotropic polypeptide (GIP)
9.2. Adipsinresistin
9.3. Cholesteryl Ester Transfer Protein (CETP)
9.4. Adiponectin
9.5. Leptin
9.6. Cholezystokinin (CCK)
9.7. Acylation Stimulating Protein (ASP)
10.1. Lipids and apolipoproteins, namely:
10.2. VLDL, total
10.3. LDL- and HDL-cholesterol
10.4. Lipoprotein a (Lp [a])
10.5 Lipoprotein lipase (LpL)
10.6. Apoliprotein AI, AII, and B100
10.7. Fatty acid pattern in cholesteryl esters
10.8. Phospholipids
11. Oxidative modification of lipids and oxidative stress, namely:
11.1. Oxidised LDL
11.2. isoprostanes
11.3. LDL-induced adhesion molecule expression
11.4. Platelet-Activating Factor (PAF)
11.5. total glutathione in erythrocytes,paraoxonase
11.6. Platelet-Activating Factor AcetylHydrolase (PAF-AH)
12. Inflammatory parameters, namely:
12.1. C-reactive protein (CRP)
12.2. Vascular Cell Adhesion Molecule (VCAM)
12.3. InterCellular Adhesion Molecule (ICAM)
12.4. E-selectin, InterLeukin-6 (IL-6)
12.5. Tumor Necrosis Factor-α (TNFα)
12.6. Monocyte Chemoattractant Protein-1 (MCP-1)
12.7. Vascular Endothelial Growth Factor (VEGF)
13. Gene expression profile in adipocytes (fasting adipocyte biopsy) and monocytes (fasting monocyte isolation) by Random-Zell-RNA-assay: expression of genes which may affect lipid metabolism and inflammatory responses (arteriosclerosis)
14. Fecal flora
Overall trial start date
11/10/2006
Overall trial end date
12/07/2007
Reason abandoned
Eligibility
Participant inclusion criteria
1. Healthy male volunteers aged 45-68
2. Homozygosis of PPARγ2 P12A polymorphism
3. Member of the Metabolic Intervention Cohort Kiel (MICK)
BMI- matched controls will be recruited.
Participant type
Patient
Age group
Adult
Gender
Male
Target number of participants
40
Participant exclusion criteria
1. Participation in a clinical study with a medicament or a medicinal product within the last 30 days or simultaneous participation in another clinical examination
2. Inability to understand and to comply with the study protocol
3. Known metabolic or gastro-intestinal diseases, which affect the absorption, metabolism or excretion of food or food components
4. Condition after surgery of the gastro-intestinal tract, which affect gastro-intestinal motility
5. Hemoglobin <12 g/dL
6. Latex allergy
7. Diabetes (fasting glucose levels >125 mg/dl after repeated determination)
8. Surgery within the last 3 months, which still affects the current state of health
9. Intake of nitrate and/or calcium antagonists and/or alpha-blockers, which affect the blood pressure
10. Deformation of finger tips, which inhibits correct recording of EndoPAT
11. Illness of thyroid gland, which has metabolic and/or cardiovascular effect
12. Known hepatitis B, hepatitis C, HIV infection or chronic liver damage
13. Kidney insufficiency
14. Drug or alcohol abuse
15. Intake of drugs affecting the absorption, metabolism or excretion of food components or the gastro-intestinal motility
16. Intake of hormone preparations, particularly cortisone
17. Eating disorders, anorexia, bulimia, unusual outsider dietary habits
18. Psychiatric disorders, epilepsy, risk of suicide
19. For those who participate in adipose tissue biopsy, additionally:
19.1. Known allergies against local anaesthetics
19.2. Heart insufficiency
19.3. Coagulation dysfunction/consumption of drugs which may cause such dysfunctions
Recruitment start date
11/10/2006
Recruitment end date
12/07/2007
Locations
Countries of recruitment
Germany
Trial participating centre
Bundesforschungsanstalt für Ernährung und Lebensmittel, Standort Kiel,
Kiel
24103
Germany
Sponsor information
Organisation
Federal Research Centre for Nutrition and Food (BfEL) (Germany)
Sponsor details
Haid-und-Neu-Str. 9
Karlsruhe
76131
Germany
pbe.kiel@bfel.de
Sponsor type
Government
Website
Funders
Funder type
Government
Funder name
Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung) (Germany)
Alternative name(s)
Federal Ministry of Education and Research, BMBF
Funding Body Type
government organisation
Funding Body Subtype
federal
Location
Germany
Funder name
Federal Ministry of Food, Agriculture and Consumer Protection (Bundesministerium für Ernährung, Landwirtschaft und Verbraucherschutz) (Germany)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Funder name
Cognis GmbH (Germany)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19689798
Publication citations
-
Results
Herrmann J, Rubin D, Häsler R, Helwig U, Pfeuffer M, Auinger A, Laue C, Winkler P, Schreiber S, Bell D, Schrezenmeir J, Isomer-specific effects of CLA on gene expression in human adipose tissue depending on PPARgamma2 P12A polymorphism: a double blind, randomized, controlled cross-over study., Lipids Health Dis, 2009, 8, 35, doi: 10.1186/1476-511X-8-35.